Cellular homeostasis depends critically on the controlled degradation of proteins. Cells employ an intricate waste-disposal system to ensure that obsolete or harmful proteins are tagged for destruction and subsequently dismantled by specialized enzymes. Exploiting this natural process, molecular glues function by bridging proteins that do not normally interact, guiding harmful proteins toward degradation pathways. This elegant strategy offers an unprecedented level of selectivity and therapeutic potential, particularly for proteins that evade conventional drug targeting.

Historically, the identification of molecular glues has been serendipitous, limiting efficient exploitation across diverse therapeutic landscapes. Addressing this, a team led by Georg Winter, Scientific Director at the AITHYRA Research Institute and Adjunct Principal Investigator at CeMM in Vienna, alongside Michael Erb from the Scripps Research Institute, developed an innovative high-throughput chemical diversification technique paired with live-cell functional screening. This approach enables the rapid exploration of vast chemical modifications on an initial small molecule scaffold, uncovering variants that effectively reshape protein surfaces to foster new protein-protein interactions.

This methodology involves synthesizing thousands of molecular variants by systematically appending diverse chemical building blocks to a known protein ligand. Each variant subtly alters the ligand’s interface, potentially fostering novel contacts between the target protein and cellular degradation enzymes. Crucially, the screening is conducted in live cells without prior compound purification, using sensitive assays that report real-time degradation of the protein target. This fusion of chemical synthesis and cellular biology allows researchers to pinpoint active compounds with genuine biological efficacy from enormous chemical spaces in a highly efficient manner.

The researchers applied this cutting-edge approach to the leukemia-associated protein ENL, a critical regulator in certain aggressive forms of acute leukemia. Screening thousands of ligand derivatives led to identifying a compound that selectively induces robust degradation of ENL in leukemia cells. Subsequent investigations demonstrated that this compound reprograms the protein’s interaction landscape, promoting recruitment of a ubiquitin ligase complex responsible for tagging ENL with ubiquitin molecules, effectively marking it for destruction by the proteasome.

Fundamental to the activity of these compounds is their cooperative binding mechanism, a hallmark of molecular glues. Rather than indiscriminately binding to both partners, the molecule binds the target protein first, then facilitates a new interface that recruits the enzymatic degradation machinery. This mechanism underpins both the specificity and efficacy of the induced protein degradation, minimizing off-target effects and enhancing therapeutic potential.

The successful targeted degradation of ENL elucidates the enormous promise held by molecular glue technology. By precisely ablating proteins driving leukemia progression, this approach curtails malignant cell growth and opens pathways for new leukemia treatments with potentially fewer side effects compared to current therapies. Moreover, the demonstration that high-throughput ligand diversification and functional screening can yield such potent glues paves the way for broad applications across a spectrum of diseases.

The implications of this work extend far beyond ENL and leukemia. The generalizable workflow combining scalable chemical innovation with phenotype-based cellular screening transforms the paradigm of proximity-inducing drug discovery. Where once the hunt for molecular glues was slow and hit-or-miss, it can now be approached rationally with vast chemical libraries tested directly in biological contexts, accelerating the translation from molecule to medicine.

Georg Winter emphasizes that this breakthrough sets the foundation for a new era in drug design, making it feasible to target proteins, once deemed ‘undruggable,’ with small molecules that enlist the cell’s own degradation machinery for therapeutic benefit. This extends the druggable proteome dramatically, enabling intervention in diseases where pathogenic proteins have historically eluded pharmacological control.

Furthermore, the integration of artificial intelligence and next-generation automated chemistry platforms at institutions like AITHYRA will likely amplify this approach’s efficiency and breadth. The convergence of AI-driven design, robotic synthesis, and live-cell functional assays creates a powerful ecosystem to systematically identify molecular glues tailored to diverse therapeutic targets, accelerating drug discovery timelines significantly.

As molecular glues gain traction in both academic and pharmaceutical sectors, the strategy heralded by this study could revolutionize how diseases such as cancer, neurodegeneration, and viral infections are treated. Through rational, scalable ligand diversification paired with cell-based functional screening, there is newfound optimism that targeted protein degradation can become a mainstay of precision medicine, offering customized therapies with high specificity and minimal side effects.

This landmark study, published in Nature Chemical Biology, underscores the transformative potential of combining high-throughput chemistry with live-cell biology to unlock new drug modalities. The systematic discovery of molecular glues not only represents a technical tour de force but also a conceptual leap forward, fostering a deeper understanding of protein interactions and cellular degradation pathways that can be leveraged for therapeutic innovation.

The impact of these findings is already resonating through the scientific community, evoking excitement about the possibilities molecular glues hold for treating a vast array of diseases. As this platform matures, it promises to illuminate previously dark corners of the proteome, making the impossible task of targeting elusive proteins a tangible reality.

Subject of Research: Cells

Article Title: High-throughput ligand diversification to discover chemical inducers of proximity

News Publication Date: February 16, 2026

Web References:
https://doi.org/10.1038/s41589-025-02137-2

References:
Shaum JB, Muñoz i Ordoño M, Steen EA, et al. High-throughput ligand diversification to discover chemical inducers of proximity. Nature Chemical Biology. 2026; DOI:10.1038/s41589-025-02137-2.

Image Credits: © Miquel Muñoz

Keywords: Leukemia, Proteins, Molecular glues, Targeted protein degradation, High-throughput screening, Chemical biology, Drug discovery, Acute leukemia, Ubiquitin ligase, ENL protein

Albrecht’s pioneering research delves into the intricate mechanisms that govern how cells regulate protein function and degradation. At the heart of her work is the process of methylation, a biochemical modification that has historically been neglected in discussions surrounding lysosomal proteolysis. This oversight has prevented a comprehensive understanding of critical cellular processes, but Albrecht’s exploration seeks to rectify this gap. By elucidating the role of methylation, her findings could fundamentally shift our comprehension of cellular signaling pathways and protein homeostasis.

The implications of Albrecht’s work extend far beyond mere academic curiosity. The pathways she investigates have potential clinical relevance, particularly in understanding genetic heart diseases—a spectrum of disorders that can lead to devastating health outcomes. By deciphering the way in which proteins are regulated within cells, there exists the promise of developing new therapeutic strategies that could mitigate the effects of such genetic conditions. This translational aspect of her research remains a cornerstone of its significance; it holds the promise not just for enhanced scientific comprehension but also for tangible benefits to patient care.

The recognition of Albrecht’s work comes with strong endorsements from her colleagues. Andrej Luptak, a respected professor and chair of pharmaceutical sciences at UC Irvine, has lauded her work as exceptionally relevant across various biological systems. His assertion that Albrecht is addressing fundamental questions within the domains of cell and chemical biology highlights the core of her research endeavors. The breadth of her findings underscores not only the innovative nature of her investigations but also their applicability across multiple fields of study, including those that intersect with clinical medicine.

Beyond her research, Albrecht is also committed to nurturing the next generation of researchers. She promotes diversity and inclusion within the scientific community through her involvement in the Diverse Educational Community and Doctoral Experience program. This program is crucial for supporting and mentoring Ph.D. students from underrepresented backgrounds, fostering an environment that values different perspectives and experiences in science, technology, engineering, and mathematics.

The Sloan Research Fellowship comes with financial support amounting to $75,000 over two years, which is a vital resource for early-career researchers. The funds can be utilized in various ways, allowing fellows like Albrecht the flexibility to enhance their research capabilities, whether through purchasing equipment, improving laboratory facilities, attending conferences, or hiring research staff. Such support is particularly invaluable in an academic landscape that demands innovative thinking while also contending with limited funding opportunities.

Historically, the Sloan Research Fellowship has recognized a range of talented early-career scientists, and it’s regarded as one of the most competitive and respected awards in the field. The selection of Albrecht, among 126 recipients in a given year, speaks volumes about the quality of research emerging from UC Irvine. The institution has a rich legacy, with 65 of its faculty members having received the fellowship since its inception in 1965. This impressive track record not only elevates the standing of the university but also underscores its excellence in fostering groundbreaking scientific research.

In her role as an assistant professor at UC Irvine, Albrecht’s dedication to her students adds an enriching layer to her professional portfolio. Her mentorship is transforming the educational experience for the next generation, inspiring them to engage with science actively and pursue their passions in research. This commitment to education highlights a dual focus that is indeed vital for the progression of scientific inquiry.

The implications of Albrecht’s discoveries stretch into the broader dimensions of understanding cellular processes, particularly for diseases that afflict millions globally. As the complexity of these diseases continues to unravel, the foundation of knowledge being laid by researchers like Albrecht becomes increasingly crucial. Her emphasis on protein regulation through methylation may very well open new avenues for treatment and prevention strategies, ushering a new era of biomedical innovation.

As we look toward the future, the work being conducted by early-career scientists like Albrecht is a testament to the potential for science to change lives. In a rapidly advancing technological landscape, interdisciplinary approaches that bridge basic research with clinical applications are essential. Albrecht’s research not only pursues scientific excellence but also embodies the ethical responsibility that modern scientists carry—employing their knowledge and skills to improve human health and well-being.

The recognition by the Alfred P. Sloan Foundation not only serves as an acknowledgment of Albrecht’s impressive accomplishments thus far but also emphasizes the critical importance of sustained support for early-career researchers. With adequate funding and institutional backing, the possibilities for innovation and discovery are limitless. As Albrecht continues to advance her research, the scientific community eagerly anticipates the fruit of her rigorous inquiry and its potential to transform our understanding of cellular biology.

As Albrecht’s research journey unfolds, her contributions highlight the transformative power of science, driven by curiosity, creativity, and a collective commitment to addressing humanity’s challenges. The future of scientific research is being shaped by visionary thinkers like her, who not only excel in their fields but also inspire and empower those who will follow in their footsteps.

Subject of Research: Methylation in Cell Signaling and Protein Homeostasis
Article Title: Innovative Research in Cell and Chemical Biology: Lauren Albrecht Awarded Sloan Research Fellowship
News Publication Date: February 20, 2025
Web References: University of California, Irvine, U.S. News & World Report
References: Alfred P. Sloan Foundation, UCI News
Image Credits: N/A

Keywords

Early career scientists, Chemical biology, Protein regulation, Methylation, Diversity in STEM, Genetic heart disease, Therapeutic strategies